Relmada Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Relmada Therapeutics, Inc. announced on September 16, 2025, that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The company received written notice from Nasdaq confirming that its common stock had maintained a closing bid price of $1.00 or greater for 10 consecutive trading days, from August 29, 2025, to September 12, 2025. As a result, Nasdaq has closed the matter, and Relmada is now in full compliance with all Nasdaq continued listing requirements. The company's stock will continue to be listed and traded on the Nasdaq Capital Market under the ticker symbol 'RLMD.' Relmada Therapeutics is a clinical-stage biotechnology company focused on developing therapies for oncology-related and central nervous system conditions.